Cambridge Investment Research Advisors
AMAG

Cambridge Investment Research Advisors’s AMAG Pharmaceuticals AMAG Stock Holding History

Cambridge Investment Research Advisors’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-12,000
Closed -$234K – 2331
2018
Q2 		$234K Hold
12,000
– – ﹤0.01% 1903
2018
Q1 		$242K Sell
12,000
-175
-1% -$2.96K ﹤0.01% 1839
2017
Q4 		$161K Buy
+12,175
New +$184K ﹤0.01% 1980

Other funds holding AMAG

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Cambridge Investment Research Advisors's AMAG Position: Q3 2018 in Review

Cambridge Investment Research Advisors sold out of AMAG Pharmaceuticals (AMAG) in Q3 2018, closing a stake of 12,000 shares — an estimated $234K sold.

Cambridge Investment Research Advisors first reported a position in AMAG in Q4 2017 and held it in 3 quarters. The position peaked at $242K in Q1 2018. 182 funds tracked by Wall St. Rank hold AMAG as of Q3 2018.

  • Cambridge Investment Research Advisors reported no remaining AMAG Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 12,000 AMAG Pharmaceuticals shares in Q3 2018, an estimated $234K.
  • Cambridge Investment Research Advisors first reported a position in AMAG Pharmaceuticals in Q4 2017 and held it in 3 quarters.
  • Cambridge Investment Research Advisors's AMAG Pharmaceuticals position peaked at $242K in Q1 2018.
  • 182 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q3 2018.

Based on Cambridge Investment Research Advisors's 13F filing for Q3 2018, filed 2 Nov 2018.